The PCSK9* inhibitor alirocumab reduced low-density lipoprotein cholesterol (LDL-C) levels and several other lipid parameters in patients with type 2 diabetes (T2D) and high cardiovascular risk, according to two studies presented at the 77th Scientific Sessions of the American Diabetes Association (ADA 2017) held in San Diego, California, US.
More frequent text messaging responses to reminders to check blood glucose (BG) was associated with better glycaemic control in teens with type 1 diabetes (T1D), and may help the transition from paediatric to adult care which entails greater self-care routine, suggests a study presented at the American Diabetes Association’s 77th Scientific Sessions held in San Diego, California, US.
A single dose of the human glucagon receptor (GCGR) antibody, REMD-477, reduces the amount of insulin necessary and significantly improves glycaemic control in individuals with type 1 diabetes (T1D), according to a study presented at the ADA 2017 in San Diego, California, US.
Severe obesity in children and adolescents may increase the risk of developing youth-onset diabetes, according to a study presented at the American Diabetes Association’s 77th Scientific Sessions held in San Diego, California, US.
Insulin degludec had comparable cardiovascular safety and reduced the risk of severe hypoglycaemia compared with insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk, according to results of the DEVOTE* study.
Individuals with high fasting plasma glucose (FPG) lost more weight than those who had low FPG in response to a high-fibre, low glycaemic load diet, suggesting that FPG could be used as a biomarker to predict dietary weight loss success and to guide selection of the most effective diet, in particular for those with prediabetes and diabetes, according to studies presented at ADA 2017.
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).